

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-29 (canceled)

30. (Currently amended) An isolated human antibody or antigen binding fragment antibody fragment, ~~wherein the antibody or antibody fragment is encoded by a nucleic acid which encodes a heavy chain, which is able to bind to a GPIIb/IIIa complex, of a human antibody or a fragment thereof, and wherein the heavy chain of said antibody comprises a CDR3 region a CDR2 region and a CDR1 region, wherein said CDR3 region is encoded by a nucleotide sequence selected from the group consisting of:~~

(a) a nucleotide sequence which encodes the amino acid sequence:

V L P F D P I S M D V (SEQ ID NO:31), and

(b) a nucleotide sequence which encodes the amino acid sequence

A L G S W G G W D H Y M D V (SEQ ID NO:32), and

and said CDR1 region is encoded by a nucleotide sequence selected from the group consisting of:

(c) a nucleotide sequence which encodes the amino acid sequence:

G Y S W R (SEQ ID NO: 33), and

(d) a nucleotide sequence which encodes the amino acid sequence:

S Y A M H (SEQ ID NO: 34),

and said CDR2 region is encoded by a nucleotide sequence selected from the group consisting of:

(e) a nucleotide sequence which encodes the amino acid sequence:

D I S Y S G S T K Y K P S L R S (SEQ ID NO: 35), and

(f) a nucleotide sequence which encodes the amino acid sequence:

V I S Y D G S N K Y Y A D S V K G (SEQ ID NO: 36)

~~(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80% with an amino acid sequence from (a) or (b).~~

31. (Currently amended) The antibody or antibody antigen binding fragment according to claim 30, wherein said antibody includes further comprising the variable domain of the H chain and/or the variable domain of the L chain of a human antibody.

32. (Canceled)

33. (Currently amended) The antibody or antibody antigen binding fragment according to claim 30, wherein it is coupled to a detectable labeling group or a toxin.

34. (Currently amended) A composition comprising an antibody or antibody antigen binding fragment according to claim 30, in combination with adjuvants, additives or excipients.

35. (Currently amended) The antibody or antibody antigen binding fragment according to claim 30, further comprising in combination with a second human antibody or antibody antigen binding fragment subunit encoded by a nucleic acid which encodes which includes a light chain, which wherein said light chain is able to bind to GPIIb/IIIa of a human antibody or a fragment thereof, and wherein the light chain comprises a CDR3 region, a CDR2 region and a CDR1 region, wherein said CDR3 region is encoded by a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence which encodes the amino acid sequence:

A T W D D G L N G P V (SEQ ID NO:37), and

(b) a nucleotide sequence which encodes the amino acid sequence

A A W D D S L N G W V (SEQ ID NO:38), and

and said CDR1 region is encoded by a nucleotide sequence selected from the group consisting of:

(c) a nucleotide sequence which encodes the amino acid sequence:

S G S S S N I R S N P V S (SEQ ID NO: 39), and

(d) a nucleotide sequence which encodes the amino acid sequence:

S G S S S N I G S N T V N (SEQ ID NO: 40),

and said CDR2 region is encoded by a nucleotide sequence selected from the group consisting of:

(e) a nucleotide sequence which encodes the amino acid sequence:

G S H Q R P S (SEQ ID NO: 41), and

(f) a nucleotide sequence which encodes the amino acid sequence:

S N N Q R P S (SEQ ID NO: 42)

~~(e) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80% with an amino acid sequence from (a) or (b).~~

36. (Currently amended) A composition comprising an antibody or ~~antibody antigen binding~~ fragment according to claim 35 in combination with adjuvants, additives or excipients.